A
Alla Polotskaia
Researcher at City University of New York
Publications - 14
Citations - 1045
Alla Polotskaia is an academic researcher from City University of New York. The author has contributed to research in topics: Cell culture & Chromatin. The author has an hindex of 8, co-authored 14 publications receiving 875 citations. Previous affiliations of Alla Polotskaia include The Graduate Center, CUNY & Hunter College.
Papers
More filters
Journal ArticleDOI
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway
William A. Freed-Pastor,Hideaki Mizuno,Xi Zhao,Anita Langerød,Sung Hwan Moon,Ruth Rodriguez-Barrueco,Anthony M. Barsotti,Agustin Chicas,Wencheng Li,Alla Polotskaia,Mina J. Bissell,Timothy F. Osborne,Bin Tian,Scott W. Lowe,Jose M. Silva,Anne Lise Børresen-Dale,Anne Lise Børresen-Dale,Arnold J. Levine,Jill Bargonetti,Carol Prives +19 more
TL;DR: It is found that mutant p53 depletion is sufficient to phenotypically revert breast cancer cells to a more acinar-like morphology, which implicate the mevalonate pathway as a therapeutic target for tumors bearing mutations in p53.
Journal ArticleDOI
A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation
TL;DR: The novel finding that p53 was not the key target of Mdm2 in the estrogen activation of cell proliferation could have great benefit for future MDM2-targeted breast cancer therapies.
Journal ArticleDOI
Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4.
Alla Polotskaia,Gu Xiao,Katherine Reynoso,Che L. Martin,Wei-Gang Qiu,Ronald C. Hendrickson,Jill Bargonetti +6 more
TL;DR: The addition of mtp53 proteomic targets to the previously identified transcriptional targets suggests that effective treatment of mTP53-driven breast cancers may be facilitated by new combination protocols blocking proteins of the metabolic pathways of cholesterol biosynthesis, DNA replication, and DNA repair.
Journal ArticleDOI
Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer
Wei-Gang Qiu,Wei-Gang Qiu,Alla Polotskaia,Gu Xiao,Lia Di,Yuhan Zhao,Wenwei Hu,John Philip,Ronald C. Hendrickson,Jill Bargonetti,Jill Bargonetti +10 more
TL;DR: It is reported that the heterohexomeric minichromosome maintenance complex that participates in DNA replication initiation ranked as a high mutant p53-chromatin associated pathway and may be useful for theranostics.
Journal ArticleDOI
Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer.
Gu Xiao,Devon Lundine,George K. Annor,Jorge Canar,Viola Ellison,Alla Polotskaia,Patrick L. Donabedian,Thomas Reiner,Thomas Reiner,Galina Khramtsova,Olufunmilayo I. Olopade,Alexander Mazo,Jill Bargonetti,Jill Bargonetti +13 more
TL;DR: The results indicate that mtp53 R273H and PARP1 interact with replicating DNA and should be considered as dual biomarkers for identifying breast cancers that may respond to combination PARPi treatments.